Literature DB >> 24296680

Bone diseases: Sclerostin neutralization--a viable pathway for OPPG?

Bryony Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24296680     DOI： 10.1038/nrrheum.2013.189

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Authors:  Rajendra Kedlaya; Shreya Veera; Daniel J Horan; Rachel E Moss; Ugur M Ayturk; Christina M Jacobsen; Margot E Bowen; Chris Paszty; Matthew L Warman; Alexander G Robling
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.